Psilera Raises $8.8 Million in Seed Funding
Tampa-based biotechnology company Psilera has successfully raised $8.8 million in a seed funding round. Specializing in developing innovative treatments for neurological disorders, Psilera aims to pioneer a new class of neuroplastogens, which hold promise for addressing various neurological conditions.
Company Background
Founded by Chris Witowski, PhD, who serves as the CEO, and Jackie von Salm, PhD, the Chief Scientific Officer, Psilera is at the forefront of biotechnological advancements targeting neurological health. The company is committed to creating first-in-class treatments that leverage the potential of neuroplastogens, offering new hope for patients with neurological challenges.
Details of the Funding Round
The seed funding round, completed on May 28, 2026, did not specify any lead investors or additional participating investors. Despite the lack of publicized investor details, the substantial amount raised reflects significant confidence in Psilera's research and development capabilities.
Planned Use of Funds
While specific plans for the newly acquired funds have not been disclosed, companies in this sector typically allocate seed funding to accelerate research and development activities, enhance their scientific teams, and potentially expand their operational capabilities. Given Psilera's focus, it is likely that the funds will be used to further develop their neuroplastogen treatments and advance clinical trials.
Outlook
With this latest infusion of capital, Psilera is well-positioned to make substantial progress in their mission to revolutionize the treatment landscape for neurological disorders. As they continue to innovate in this promising field, stakeholders and potential patients alike will be watching closely to see the impact of their groundbreaking work.